Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 30.06.2025 1 Am J Clin Oncol 1 Am J Pathol 3 Am J Surg 2 Ann Oncol 6 Ann Surg Oncol 2 Anticancer Res 1 BMJ Oncol 3 Breast Cancer 5 Breast Cancer Res 5 Breast Cancer Res Treat 1 Cancer Chemother Pharmacol 4 Clin Breast Cancer 1 Clin Cancer Res 3 Eur J Surg Oncol 2 Eur Radiol 2 Gene 3 Int J Cancer 1 Int J Radiat Oncol Biol Phys 2 J Biol Chem 4 J Surg Oncol 1 Lancet Oncol 4 NPJ Breast Cancer 11 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Radiol Imaging Cancer 2 Radiology 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. IQBAL H, Juneja B, Chryssofos S, Ahlawat S, et al
   Complications of Implant-Based Reconstruction and Postmastectomy Radiation in the Era of Adjuvant CDK4/6 Inhibitors.
   Am J Clin Oncol. 2025;48:357-361.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. LU N, Zhang M, Lu L, Liu YZ, et al
   Retraction Notice to "Insulin-Induced Gene 2 Expression Is Associated with Breast Cancer Metastasis" [Am J Pathol 191 (2021) 385-395].
   Am J Pathol. 2025;195:1358.
   PubMed        
   
   

   
   Am J Surg

3. RADEMACHER N, McLeod MC, Williams CP, Awan S, et al
   Association between travel burden and surgical timeliness for women with breast cancer in Georgia.
   Am J Surg. 2025;247:116484.
   PubMed         Abstract available
   
   
4. JIANG JG, Agarwal T, Higgins MG, Roy MK, et al
   Identifying resource needs of patients with breast cancer by examining alignment of Reddit post content with BREAST-Q domains.
   Am J Surg. 2025;247:116486.
   PubMed         Abstract available
   
   
5. EGBERT LK, Kosiorek H, Cronin P, Billar J, et al
   Trends in axillary staging for breast cancer in the elderly: Outcomes of choosing wisely at a high-usage institution.
   Am J Surg. 2025;250:116477.
   PubMed         Abstract available
   
   

   
   Ann Oncol

6. ZHU X, Zhu T, Gu X
   Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
   Ann Oncol. 2025 Jun 20:S0923-7534(25)00816-6. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
7. HU Q, Yang X
   Navigating the Limits of Ribociclib in Early Breast Cancer: Questions from the NATALEE Trial.
   Ann Oncol. 2025 Jun 23:S0923-7534(25)00815-4. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   

   
   Ann Surg Oncol

8. OSHI M, Ghasemi F, Yamada A, Yan L, et al
   Activated Hippo Pathway is Associated with a Worse Response to Trastuzumab and Worse Survival in HER2-Positive Breast Cancer.
   Ann Surg Oncol. 2025 Jun 21. doi: 10.1245/s10434-025-17657.
   PubMed         Abstract available
   
   
9. YAO J, Li H, Wang H, Liu B, et al
   Lymphatic Contrast-enhanced Ultrasound as a Noninvasive Predictor of Sentinel Lymph Node Metastasis in Breast Cancer: A Prospective Diagnostic Study.
   Ann Surg Oncol. 2025 Jun 23. doi: 10.1245/s10434-025-17705.
   PubMed         Abstract available
   
   
10. SILVERSTEIN MJ, Kim B, Lin K, Lloyd S, et al
    ASO Visual Abstract: Intraoperative Radiation Therapy (IORT) for Breast Cancer: The Final Analysis of a Prospective Cohort of 1828 Cases.
    Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17698.
    PubMed        
    
    
11. NGUYEN CL, Poels D, Teoh B, Rastogi P, et al
    Indocyanine Green Fluorescence-Guided Axillary Reverse Mapping for Axillary Lymph Node Dissection in Breast Cancer: The FARM Trial.
    Ann Surg Oncol. 2025 Jun 23. doi: 10.1245/s10434-025-17703.
    PubMed         Abstract available
    
    
12. NIERENBERG TC, Plichta JK
    ASO Author Reflections: Adjuvant Therapy Options for Older Women with Early Stage Breast Cancer.
    Ann Surg Oncol. 2025 Jun 23. doi: 10.1245/s10434-025-17732.
    PubMed        
    
    
13. HSIEH YC, Huang CS, Chan YH
    A Dose-Image Optimization Trial for Voluven(R)-Assisted Indocyanine Green Fluorescence-Guided Breast Cancer Sentinel Lymph Node Surgery.
    Ann Surg Oncol. 2025 Jun 23. doi: 10.1245/s10434-025-17696.
    PubMed         Abstract available
    
    

    
    Anticancer Res

14. KAMYAN D, Elemam NM, Alkhayyal N, Talaat IM, et al
    Unlocking New Frontiers in Breast Cancer: The Role of the Tumor Microenvironment, Cutting-Edge Therapies, and Immunotherapy.
    Anticancer Res. 2025;45:2729-2747.
    PubMed         Abstract available
    
    
15. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed         Abstract available
    
    

    
    BMJ Oncol

16. EARL HM, Hiller L, Dunn JA, Patel M, et al
    Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.
    BMJ Oncol. 2025;4:e000810.
    PubMed         Abstract available
    
    

    
    Breast Cancer

17. KUL KOPRULU T, Aras S, Erkal Cam B, Kara A, et al
    Comparison of transcriptome profiles of radiotherapy beams on MCF-7 breast cancer xenografts.
    Breast Cancer. 2025 Jun 27. doi: 10.1007/s12282-025-01735.
    PubMed         Abstract available
    
    
18. HUANG M, Zhang J, Yan C, Ling R, et al
    KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.
    Breast Cancer. 2025 Jun 24. doi: 10.1007/s12282-025-01737.
    PubMed         Abstract available
    
    
19. YOSHINAMI T, Takano Y, Ozaki Y, Kajiwara Y, et al
    Correction: Real?world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first? or second?line treatment for hormone receptor-positive, HER2?negative advanced or met
    Breast Cancer. 2025 Jun 23. doi: 10.1007/s12282-025-01736.
    PubMed        
    
    

    
    Breast Cancer Res

20. CAIRAT M, Olesen M, Olivier E, Pottegard A, et al
    Systemic glucocorticoids and the risk of breast cancer in a large nationwide case-control study.
    Breast Cancer Res. 2025;27:114.
    PubMed         Abstract available
    
    
21. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2025;27:116.
    PubMed        
    
    
22. LEON-FERRE RA, Dimitroff K, Yau C, Giridhar KV, et al
    Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Breast Cancer Res. 2025;27:115.
    PubMed         Abstract available
    
    
23. CORRADO A, Lorito N, Anemone A, Carella A, et al
    In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer.
    Breast Cancer Res. 2025;27:112.
    PubMed         Abstract available
    
    
24. RYU S, Kim HS, Lee S, Yoon SH, et al
    Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models.
    Breast Cancer Res. 2025;27:113.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

25. KOLBOW M, Luo Q, Cerrato Grande A, Marmor S, et al
    The use of indocyanine green and technetium-99 for dual-tracer sentinel lymph node biopsy in breast cancer.
    Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07767.
    PubMed         Abstract available
    
    
26. ALESSANDRA Z, Emilie L, Aline A, Marianne L, et al
    Analysis of the impact of the COVID-19 pandemic on the stage at diagnosis in breast cancer patients at a French comprehensive cancer centre, through two different methods: a preliminary study.
    Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07762.
    PubMed         Abstract available
    
    
27. ABRAHAO R, Ruddy KJ, Laurent CA, Chubak J, et al
    Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer.
    Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07760.
    PubMed         Abstract available
    
    
28. FANNING JE, Chen A, Thomson S, Tillotson E, et al
    The deltopectoral lymph node: a potential protective biomarker for breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2025 Jun 25. doi: 10.1007/s10549-025-07748.
    PubMed         Abstract available
    
    
29. ALHARBI M, Krishnan J, Roy AM, Patel A, et al
    Area deprivation index and breast cancer outcomes among patients in Western New York.
    Breast Cancer Res Treat. 2025 Jun 22. doi: 10.1007/s10549-025-07733.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

30. SALAH H, Rabea H, Sheemy MS, Rabie AI, et al
    Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial.
    Cancer Chemother Pharmacol. 2025;95:64.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

31. SHEN WR, Chen SL, Zhang ZZ
    Letter to the Editor Regarding the Article "In Triple-Negative Breast Cancer: Correlation Among Metabolic Syndrome, S100A7/cPLA2 Expression and the Efficacy of Neoadjuvant Chemotherapy".
    Clin Breast Cancer. 2025 May 30:S1526-8209(25)00147.
    PubMed        
    
    
32. CABELLO AERDS, Cabello C, Duarte BN, Alem CER, et al
    Distribution of HER2 Low in Tumors of Patients With Hereditary Breast Cancer According to Germline Pathogenic or Likely Pathogenic Genetic Variants.
    Clin Breast Cancer. 2025 May 28:S1526-8209(25)00148.
    PubMed         Abstract available
    
    
33. HERRAN M, Zabor EC, Sabbagh S, Bilani N, et al
    Disparities in Access to Multigene Testing in Early-Stage, HR-positive, HER2-negative, Lymph Node-negative Breast Cancer.
    Clin Breast Cancer. 2025 May 24:S1526-8209(25)00149.
    PubMed         Abstract available
    
    
34. SCHNELL PM, Kassem M, Miah A, Ramaswamy B, et al
    Changes in Glucose level During Chemotherapy Treatment in Patients With Stage I-IV Breast Cancer.
    Clin Breast Cancer. 2025 May 27:S1526-8209(25)00161.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

35. ROJO F, Taylor CR, Barrios C, Torrecillas L, et al
    FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial.
    Clin Cancer Res. 2025 Jun 26. doi: 10.1158/1078-0432.CCR-25-0338.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

36. KOH HW, Jung JJ, Kim HK, Moon HG, et al
    Tumor volume as a predictor of recurrence-free survival, but not overall survival, in early breast cancer.
    Eur J Surg Oncol. 2025;51:110024.
    PubMed         Abstract available
    
    
37. VILA J, Farante G, Ripoll-Orts F, Lissidini G, et al
    A retrospective study evaluating surgical upstaging rates in low-risk DCIS patients meeting the eligibility criteria for active surveillance trials.
    Eur J Surg Oncol. 2025;51:109716.
    PubMed         Abstract available
    
    
38. ALGHAZAWI LOK, Mavroveli S, Anastasiou E, Attia M, et al
    Validation of a simulator for oncoplastic breast conserving surgery.
    Eur J Surg Oncol. 2025;51:109753.
    PubMed         Abstract available
    
    

    
    Eur Radiol

39. TAIB AG, Partridge GJW, Yao L, Darker I, et al
    The evaluation of artificial intelligence in mammography-based breast cancer screening: Is breast-level analysis enough?
    Eur Radiol. 2025 Jun 25. doi: 10.1007/s00330-025-11733.
    PubMed         Abstract available
    
    
40. EOM HJ, Kim HH, Kim HJ, Choi WJ, et al
    Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer.
    Eur Radiol. 2025 Jun 24. doi: 10.1007/s00330-025-11640.
    PubMed         Abstract available
    
    

    
    Gene

41. EL-GHALI RM, Daldoul A, Zaied S, Khechine W, et al
    TLR-4 genetic variants as predictive biomarkers for susceptibility and clinical outcomes in triple-negative breast cancer: A case control study.
    Gene. 2025;964:149643.
    PubMed         Abstract available
    
    
42. THANKACHAN S, Kavitha KP, Eswaran S, Kabekkodu SP, et al
    Expression of the lncRNA NEAT1/hsa-miR-20b-5p/STAT3 axis in breast cancer.
    Gene. 2025;964:149638.
    PubMed         Abstract available
    
    

    
    Int J Cancer

43. WEI SQ, Leduc V, Potter B, Paradis G, et al
    Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70025.
    PubMed         Abstract available
    
    
44. MENZ BD, Modi ND, Abuhelwa AY, Kuderer NM, et al
    Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.
    Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70020.
    PubMed         Abstract available
    
    
45. JENSEN A, Gottschau M, Christensen J, Lindquist S, et al
    Risk of breast cancer among women with hypo- and hyperthyroidism: Results from a large nationwide cohort study.
    Int J Cancer. 2025 Jun 23. doi: 10.1002/ijc.70007.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

46. PARSONS D, Domal S, Chambers E, Salazar D, et al
    Feasibility and Impact of a Radiation Therapy Technologist-Driven Workflow for Cone Beam Computed Tomography Guided Partial Breast Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:893-901.
    PubMed         Abstract available
    
    

    
    J Biol Chem

47. LI X, Chung YM, Patel M, Sharifi N, et al
    HSD3B1 Upregulation via LRH1 Sustains Estrogen Receptor Signaling and Promotes Endocrine Resistance in Breast Cancer.
    J Biol Chem. 2025 Jun 20:110405. doi: 10.1016/j.jbc.2025.110405.
    PubMed         Abstract available
    
    
48. TANIHARA T, Yoshida Y, Ogino T, Terada Y, et al
    Microcurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer.
    J Biol Chem. 2025 Jun 24:110414. doi: 10.1016/j.jbc.2025.110414.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

49. HUANG A, Koesters E, Garza RM, Hanson SE, et al
    A Single Institution Experience With Immediate Lymphatic Reconstruction: Impact of Insurance Coverage on Risk Reduction.
    J Surg Oncol. 2025;131:1393-1399.
    PubMed         Abstract available
    
    
50. STERN CS, Shammas RL, Montes ES, Boe LA, et al
    Improving the Evaluation of Aesthetic Outcomes in DIEP Flap Breast Reconstruction: Validation of the Aesthetic Grading Tool.
    J Surg Oncol. 2025;131:1407-1412.
    PubMed         Abstract available
    
    
51. COLEMAN-BELIN JC, Kim M, Graziano FD, Boe LA, et al
    Combined Autologous Breast Reconstruction and Gynecologic Procedures: Does Timing Affect Clinical and Patient-Reported Outcomes?
    J Surg Oncol. 2025;131:1400-1406.
    PubMed         Abstract available
    
    
52. FANNING JE, Chen A, Thomson S, Tillotson E, et al
    Epitrochlear and Humeral Lymph Nodes: A Biomarker for Deep Lymphatic Function and Implications for Breast Cancer-Related Lymphedema Risk.
    J Surg Oncol. 2025 Jun 24. doi: 10.1002/jso.70002.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

53. SAITO M, Iihara H, Shimokawa M, Udagawa R, et al
    Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Oncol. 2025 Jun 17:S1470-2045(25)00233.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

54. HAN W, Kang E, Jung JG, Kim HK, et al
    Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2- breast cancer.
    NPJ Breast Cancer. 2025;11:57.
    PubMed         Abstract available
    
    
55. ALBANELL J, Pozo AG, Arteaga CL, Bellet M, et al
    Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.
    NPJ Breast Cancer. 2025;11:59.
    PubMed         Abstract available
    
    
56. NGUYEN ST, Nguyen Hoang VA, Nguyen Trieu V, Pham TH, et al
    Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer.
    NPJ Breast Cancer. 2025;11:58.
    PubMed         Abstract available
    
    
57. MEZZANOTTE-SHARPE J, Taylor BC, Gonzalez-Ericsson PI, Sanchez V, et al
    A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.
    NPJ Breast Cancer. 2025;11:61.
    PubMed         Abstract available
    
    

    
    PLoS One

58. YING J, Cattell R, Huang C
    Cross-field strength and multi-vendor reliability of MagDensity for MRI-based quantitative breast density analysis.
    PLoS One. 2025;20:e0316076.
    PubMed         Abstract available
    
    
59. MOFFETT L, Barnett AJ, Donnelly J, Schwartz FR, et al
    Multi-site validation of an interpretable model to analyze breast masses.
    PLoS One. 2025;20:e0320091.
    PubMed         Abstract available
    
    
60. BROWNSON-SMITH R, Carr J, Fox KT, Orange ST, et al
    The test-retest reliability of the H-Reflex and swaymeter in women aged 30-65 years.
    PLoS One. 2025;20:e0314437.
    PubMed         Abstract available
    
    
61. NAMBA-BANDO MDMY, Contreras-Yanez I, Tenorio-Torres JA, Pascual-Ramos V, et al
    Futility in healthcare among Mexican female patients with breast cancer in advanced stage: The patient perspective.
    PLoS One. 2025;20:e0326332.
    PubMed         Abstract available
    
    
62. ALSHAREEDA AT, Albarakati N, Alshawakir Y, Alghuwainem A, et al
    Improving the robustness and efficiency of cell sheet protocol for breast cancer induction in animal model: A Geltrex plus Gelatin approach.
    PLoS One. 2025;20:e0326456.
    PubMed         Abstract available
    
    
63. WAKS-SERRA MV, Vera DA, Carbone NA, Garcia HA, et al
    Solid breast tumors phantom emulating oxy and deoxyhemoglobin concentrations for near infrared imaging.
    PLoS One. 2025;20:e0325768.
    PubMed         Abstract available
    
    
64. JAHAN R, Bhuiyan AKMMR, Alam A, Chowdhury MK, et al
    Outcomes of complex decongestive therapy in managing upper limb lymphedema in female breast cancer patients at a palliative care unit of a tertiary care hospital in Bangladesh.
    PLoS One. 2025;20:e0326040.
    PubMed         Abstract available
    
    
65. NDJENGUE BENGONE BC, Toniolo J, Filankembo Kava AC, Ngoungou EB, et al
    Psychological repercussions of breast or uterine cervical cancer disclosure to women in Gabon.
    PLoS One. 2025;20:e0326378.
    PubMed         Abstract available
    
    
66. RUJIMONGKON K, Adchariyasakulchai P, Meeprasertskul P, Ketchart W, et al
    Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells.
    PLoS One. 2025;20:e0326742.
    PubMed         Abstract available
    
    
67. UNLU YAZICI M, Marron JS, Bakir-Gungor B, Zou F, et al
    3Mont: A multi-omics integrative tool for breast cancer subtype stratification.
    PLoS One. 2025;20:e0326154.
    PubMed         Abstract available
    
    
68. HUTCHISON RE, Smith S, Caudell C, Biddle S, et al
    Effects of chemotherapy on skeletal muscle mitochondrial oxidative capacity using near-infrared spectroscopy (NIRS): Protocol paper for an observational mixed model repeated measures design in patients with breast and gynecological cancer.
    PLoS One. 2025;20:e0315351.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

69. LIM J, Jung HD, Park SY, Jeon M, et al
    Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets.
    Proc Natl Acad Sci U S A. 2025;122:e2425384122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

70. HIRSCH L, Sutton EJ, Huang Y, Kayis B, et al
    High-performance Open-source AI for Breast Cancer Detection and Localization in MRI.
    Radiol Artif Intell. 2025 Jun 25:e240550. doi: 10.1148/ryai.240550.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

71. PESAPANE F, Rotili A, Cassano E
    Patient Perspectives on AI in Breast Cancer Screening: Reflections on Educational Influence, Cognitive Bias, and Cultural Factors.
    Radiol Imaging Cancer. 2025;7:e250243.
    PubMed        
    
    

    
    Radiology

72. WOO OH, Song SE, Choe SJ, Kim M, et al
    Invasive Breast Cancers Missed by AI Screening of Mammograms.
    Radiology. 2025;315:e242408.
    PubMed         Abstract available
    
    
73. KIM HJ, Partridge SC, Lee J, Yoen H, et al
    Erratum for: Preoperative Diagnosis of Ipsilateral and Contralateral Breast Cancer: Role of Diffusion-weighted MRI.
    Radiology. 2025;315:e259012.
    PubMed        
    
    

    
    Semin Oncol

74. MOHAMMAD SI, Theab EY, Vasudevan A, Bishoyi AK, et al
    Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment.
    Semin Oncol. 2025;52:152365.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.